Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · KALA BIO, Inc. (KALA)

KALA BIO narrows Q3 2026 net loss to about $0.8 million from $7.6 million

Positive Impact 3 of 5 earnings

KALA BIO reported preliminary, unaudited results for the quarter ended September 30, 2026, showing a net loss of approximately $0.8 million, down from $7.6 million a year earlier. Cash, cash equivalents and short-term investments were approximately $7.0 million with no debt, and the company expects to file its Form 10-Q on or about November 16, 2026. Final results may differ from these preliminary figures, which shareholders should weigh against the pending review.

Key points

  • Q3 2026 net loss of approximately $0.8 million vs. $7.6 million in Q3 2025
  • Nine-month 2026 net loss of approximately $4.0 million vs. $27.7 million in the same period of 2025
  • Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
  • Form 10-Q expected on or about November 16, 2026; results remain preliminary and unaudited

The filing

CompanyKALA BIO, Inc. (KALA)
Form8-K, current report
Filed with the SECNov 9, 2026, 9:01 AM ET
Accession number0001829126-26-012118

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 9:18 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.